Taking people in FrancePhase 2
Tests relacorilant with other treatments for gynecological cancers
Tests relacorilant with other drugs in adults with ovarian or endometrial cancer.
Key facts
- Who runs it
- Corcept Therapeutics
- Where
- Lille, Nancy, Nice, Pierre-Bénite, Plérin, and Toulouse, FranceSee the 6 sitesAlso in 7 other countries, 43 sites
- Trial code
- Registry title
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 270 people, planned
- Started
- 11 Apr 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- Relacorilant 150 mg once daily (QD)
- Nab-paclitaxel 80 mg/m^2
- Bevacizumab 10 mg/kg
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with ovarian, fallopian tube, peritoneal or endometrial cancer. Relacorilant is tested together with other cancer treatments.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Arms A and B: epithelial ovarian, primary peritoneal or fallopian tube cancer. Arm A: platinum-resistant disease. Arm B: platinum-sensitive disease that grew during PARP inhibitor treatment. Arm C: stage III or IV, recurrent or metastatic endometrial cancer.
- Earlier treatment
- Arms A and B: 1 to 3 lines of earlier cancer drug treatment. Arm B: progression during a PARP inhibitor. Arm C: earlier platinum treatment and an approved anti-PD(L)1 antibody, and 1 to 2 lines of earlier treatment for endometrial cancer.
- Biomarker or test result
- Arm C: must agree to give a tumor tissue block or recently cut sections.
Main reasons for not taking part
- Earlier trial of relacorilant
- Need for long-term or frequent corticosteroids
- Treatment with mifepristone or other glucocorticoid receptor modulators
- Surgery within 4 weeks before enrollment
- Another cancer within the last 3 years
The registry criteria, word for word
Show all 49 criteriaShow less
Who can take part
- Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential; Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Who cannot take part
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Bowel obstruction ≤12 weeks prior to study entry
- Has received a live vaccine within 30 days prior to the study start date; Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Bowel obstruction ≤12 weeks prior to study entry
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- History of other malignancy within 3 years prior to enrollment
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- History of other malignancy within 3 years prior to enrollment
- Arm A and B
- Peripheral neuropathy from any cause >Grade 1
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- Peripheral neuropathy from any cause >Grade 1
- Ascites or pleural effusions requiring therapeutic paracentesis
Where in France
Also in 7 other countries, 43 sites
- 306Lille, FranceContact: Corcept TherapeuticsTaking people
- 307Nancy, FranceContact: Corcept TherapeuticsTaking people
- 310Nice, FranceContact: Corcept TherapeuticsTaking people
- 324Pierre-Bénite, FranceContact: Corcept TherapeuticsTaking people
- 323Plérin, FranceContact: Corcept TherapeuticsTaking people
- 308Toulouse, FranceContact: Corcept TherapeuticsTaking people
About the trial
What the trial wants to find out
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
The 3 groups in the trial
- Arm A: Relacorilant in Combination with Nab-paclitaxel and BevacizumabTreatment being tested
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab.
Treatment: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, and Bevacizumab 10 mg/kg
- Arm B: Relacorilant in Combination with Nab-Paclitaxel and BevacizumabTreatment being tested
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab.
Treatment: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, and Bevacizumab 10 mg/kg
- Arm C: Relacorilant in Combination with Nab-PaclitaxelTreatment being tested
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel.
Treatment: Relacorilant 150 mg once daily (QD) and Nab-paclitaxel 80 mg/m^2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)
- Plain-language title
- Tests relacorilant with other treatments for gynecological cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 July 2026